The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Margetuximab Plus Chemotherapy in HER2+ Breast Cancer

Mark D. Pegram, MD
Published Online: 8:32 PM, Wed December 7, 2016

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women’s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses the phase III SOPHIA trial, which is exploring margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in the treatment of patients with HER2-positive breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.